Randomized Phase 3 trial.

– A presentation , experienced.lyzed the docetaxel-pretreated group in two separate ways:.. New data from Phase 3 trial in second-line castrate prostate cancer at 2009 ASCO Annual Meeting PresentedGPC Biotech AG announced today that data from the double-blind, randomized Phase 3 trial, the SPARC trial were presented at the 2009 American Society for Clinical Oncology in Orlando, Florida. The SPARC trial, satraplatin plus prednisone studied compared to placebo plus prednisone in 950 patients with castrate-resistant prostate cancer who had progressed after initial chemotherapy. The data presented are retrospective analyzes of the SPARC trial evaluating correlations between overall survival and pain at baseline, pain progression, and progression-free survival at three months.

Courtesy of you, the entire Kaiser Daily Health Policy view Report, search the archives, or sign up for email delivery at Kaiser Daily Health Policy Report strongly supports kaiser network a free service of the Henry. J posted. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.Physiotherapist on Kindred Hospital of Greensboro, yet been discovered another use for that art. Know SAM with bariatric patients – persons are astonishing overweight,’said Mark Castleberry, Director of Rehabilitation Services. ‘We have two SAM and are currently being with one up a gentleman who being over 600 pounds.